Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab with chemotherapy with or without tislelizumab versus trastuzumab with chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma
NL-OMON54341Phase 3Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastroesophageal junction adenocarcinoma comparing Trastuzumab + chemotherapy, Zanidatamab + chemotherapy and Zanidatamab + tislelizumab + chemotherapy (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2022; status: recruiting.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON54341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54341.